ALVO — Alvotech SA Share Price
0.000.00%
Last trade - 00:00- $3.71bn
- $4.89bn
- $93.38m
- 22
- 24
- 82
- 39
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 356 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 12.01 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -46.59% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 82.67 | 69.45 | 39.68 | 85.02 | 93.38 | 441.22 | 655.55 | 3.09% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- September 7th, 2021
- Public Since
- November 9th, 2020
- No. of Shareholders
- 8
- No. of Employees
- 999
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 301,481,596
- Address
- 9, Rue De Bitbourg, LUXEMBOURG, 1273
- Web
- https://www.alvotech.com/
- Phone
- Auditors
- Deloitte ehf.
Upcoming Events for ALVO
Q3 2024 Alvotech SA Earnings Call
Similar to ALVO
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
FAQ
What is the Alvotech SA share price?
As of Today at 19:11 UTC, shares in Alvotech SA are trading at $12.30. This share price information is delayed by 15 minutes.
How has the Alvotech SA share price performed this year?
Shares in Alvotech SA last closed at $12.30 and the price had moved by +35.16% over the past 365 days. In terms of relative price strength the Alvotech SA share price has outperformed the S&P500 Index by +1.26% over the past year.
What are the analyst and broker recommendations for Alvotech SA?
The overall consensus recommendation for Alvotech SA is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Alvotech SA dividend yield?
Alvotech SA does not currently pay a dividend.
Does Alvotech SA pay a dividend?
Alvotech SA does not currently pay a dividend.
When does Alvotech SA next pay dividends?
Alvotech SA does not currently pay a dividend.
How do I buy Alvotech SA shares?
To buy shares in Alvotech SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Alvotech SA?
As of the previous close price of $12.30, shares in Alvotech SA had a market capitalisation of $3.71bn.
Where are Alvotech SA shares listed?
Here are the trading details for Alvotech SA:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ALVO
What kind of share is Alvotech SA?
Based on an overall assessment of its quality, value and momentum Alvotech SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Alvotech SA share price forecast for 2024?
The analyst consensus target price for shares in Alvotech SA is $19.00. That is 54.47% above the last closing price of $12.30.
Analysts covering Alvotech SA currently have a consensus Earnings Per Share (EPS) forecast of -$0.47 for the next financial year.
Find out moreWhat is the trend in the Alvotech SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alvotech SA. Over the past six months, its share price has underperformed the S&P500 Index by -7.43%.
As of the last closing price of $12.30, shares in Alvotech SA were trading -5.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Alvotech SA PE Ratio?
The Alvotech SA PE ratio based on its reported earnings over the past 12 months is 356. The shares last closed at $12.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Alvotech SA?
We do not have data on Alvotech SA's directors